Related Experiment Videos
Bone marrow transplantation experience for children with aplastic anemia
Insights
This study on bone marrow transplants for severe aplastic anemia found that avoiding graft-versus-host disease significantly improves survival. Untransfused patients showed better outcomes than transfused patients.
Area of Science:
- Hematology
- Immunology
- Pediatric Oncology
Background:
- Severe aplastic anemia is a life-threatening condition requiring bone marrow transplantation.
- Allogeneic bone marrow transplantation from HLA-identical family members is a potential curative option.
- Understanding factors influencing graft survival and rejection is crucial for improving outcomes.
Purpose of the Study:
- To evaluate the long-term survival and outcomes of pediatric patients undergoing allogeneic bone marrow transplantation for severe aplastic anemia.
- To identify factors associated with graft survival, rejection, and graft-versus-host disease.
Main Methods:
- Retrospective analysis of 81 children (22 months to 17 years) receiving HLA-identical allogeneic bone marrow grafts between 1971 and 1981.
- Patients were conditioned with cyclophosphamide, with variations in transfusion status, additional immunosuppression, and buffy coat cell administration.
- Multivariate analysis was used to identify significant prognostic factors.
Main Results:
- Overall survival was 70% (57/81) at the end of the study period.
- Untransfused patients conditioned with cyclophosphamide had an 83% survival rate (19/23) from 5 to 12 years.
- Absence of significant graft-versus-host disease was the only factor significantly associated with increased survival (P < .0001).
- Low bone marrow cell dose and positive mixed leukocyte culture response were linked to increased rejection (P < .05 and P < .0001, respectively).
- Grades II-IV acute graft-versus-host disease correlated with platelet refractoriness and donor/recipient sex differences (P < .05).
- Chronic graft-versus-host disease risk increased with acute graft-versus-host disease and buffy coat infusions (P < .01 and P < .025).
Conclusions:
- Allogeneic bone marrow transplantation can achieve long-term survival in children with severe aplastic anemia.
- Minimizing graft-versus-host disease is paramount for successful engraftment and improved survival.
- Pre-transplant conditioning, transfusion status, and donor-recipient characteristics significantly impact transplant outcomes.
Abstract:
From May 1971 through December 1981, 81 children (22 months to 17 years of age) received allogeneic bone marrow grafts for severe aplastic anemia. All donors were HLA-identical family members. Fifty-seven of the 81 (70%) are still alive. Twenty-three untransfused patients were conditioned with cyclophosphamide, 50 mg/kg/d, for four days, and 19 (83%) have survived from 5 to 12 years. All 58 transfused patients were conditioned with cyclophosphamide, 50 mg/kg/d, for four days, 11 received additional immunosuppression, and 19 received posttransplantation donor buffy coat cells. Thirty-eight (65%) have survived from 3 to 13 years (P = .1). In a multivariate analysis, the only factor significantly associated with increased survival among patients with sustained grafts was the absence of significant graft v host disease (P less than .0001). The factors significantly related to increased rejection were low bone marrow cell dose (P less than .05) and positive relative response in mixed leukocyte culture (P less than .0001), but the addition of buffy coat cells did not significantly influence graft rejection. The development of grades II to IV acute graft v host disease was associated with random donor platelet refractoriness (P less than .05) and donor/recipient sex differences (P less than .05). Patients at highest risk for chronic graft v host disease were those patients who developed significant acute graft v host disease (P less than .01) and who received buffy coat infusions (P less than .025). All patients who were untransfused had a negative relative response and were not refractory to random donor platelets.